article thumbnail

Cell and Gene Therapy Bioassay – A Prerequisite for the ATMPs Development

Roots Analysis

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Bioassays are biochemical procedures that are used to evaluate the potency, purity and efficacy of a drug substance.

article thumbnail

Toregem BioPharma and WuXi Biologics to partner for antibody development

Pharmaceutical Technology

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Additionally, WuXi Biologics will help the company with the development of the anti-USAG-1 antibody for Investigational New Drug (IND) application.

Antibody 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Next week: Accelerate development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

article thumbnail

Exclusive event: Accelerate the development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

article thumbnail

Benefits of higher throughput bioanalytical methods in advanced therapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

article thumbnail

How to accelerate the development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.